{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T12:38:54Z","timestamp":1782131934281,"version":"3.54.5"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:00:00Z","timestamp":1707523200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:00:00Z","timestamp":1707523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-024-02312-w","type":"journal-article","created":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T05:02:41Z","timestamp":1707541361000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["The combined anti-tumor effects of 5-fluorouracil and neurokinin receptor inhibitor, aprepitant, against colorectal cancer: In vitro and in vivo study"],"prefix":"10.1007","volume":"41","author":[{"given":"Abbas","family":"Alalikhan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Safieh","family":"Ebrahimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Aliee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farshad","family":"Mirzavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Isaac","family":"Hashemy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,10]]},"reference":[{"key":"2312_CR1","doi-asserted-by":"publisher","first-page":"101174","DOI":"10.1016\/j.tranon.2021.101174","volume":"14","author":"Y Xi","year":"2021","unstructured":"Xi Y, Xu P. Global colorectal cancer burden in 2020 and projections to 2040. Transl Oncol. 2021;14:101174. https:\/\/doi.org\/10.1016\/j.tranon.2021.101174","journal-title":"Transl Oncol"},{"key":"2312_CR2","doi-asserted-by":"publisher","unstructured":"Hossain MS, Karuniawati H, Jairoun AA, Urbi Z, Ooi J, John A, Lim YC, Kibria KMK, Mohiuddin AKM, Ming LC, Goh KW. Hadi,Colorectal Cancer: a review of Carcinogenesis, Global Epidemiology, Current challenges, risk factors, preventive and treatment strategies. Cancers (Basel). 2022;14. https:\/\/doi.org\/10.3390\/cancers14071732","DOI":"10.3390\/cancers14071732"},{"key":"2312_CR3","first-page":"89","volume":"14","author":"P Rawla","year":"2019","unstructured":"Rawla P, Sunkara T. Barsouk,Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors. Gastroenterol Review\/Przegl\u0105d Gastroenterologiczny. 2019;14:89\u2013103.","journal-title":"Gastroenterol Review\/Przegl\u0105d Gastroenterologiczny"},{"key":"2312_CR4","doi-asserted-by":"publisher","first-page":"107447","DOI":"10.1016\/j.pharmthera.2019.107447","volume":"206","author":"S Vodenkova","year":"2020","unstructured":"Vodenkova S, Buchler T, Cervena K, Veskrnova V, Vodicka P. Vymetalkova,5-fluorouracil and other fluoropyrimidines in colorectal cancer: past, present and future. Pharmacol Ther. 2020;206:107447.","journal-title":"Pharmacol Ther"},{"key":"2312_CR5","doi-asserted-by":"publisher","first-page":"111285","DOI":"10.1016\/j.biopha.2021.111285","volume":"137","author":"C Sethy","year":"2021","unstructured":"Sethy C. Kundu,5-Fluorouracil (5-FU) resistance and the new strategy to enhance the sensitivity against cancer: implication of DNA repair inhibition. Biomed Pharmacother. 2021;137:111285.","journal-title":"Biomed Pharmacother"},{"key":"2312_CR6","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/nrc1074","volume":"3","author":"DB Longley","year":"2003","unstructured":"Longley DB, Harkin DP. Johnston,5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003;3:330\u20138. https:\/\/doi.org\/10.1038\/nrc1074","journal-title":"Nat Rev Cancer"},{"key":"2312_CR7","doi-asserted-by":"publisher","first-page":"659","DOI":"10.7150\/ijms.24453","volume":"15","author":"J Sanchez-Gundin","year":"2018","unstructured":"Sanchez-Gundin J, Fernandez-Carballido AM, Martinez-Valdivieso L, Barreda-Hernandez D. Torres-Suarez,New trends in the Therapeutic Approach to Metastatic Colorectal Cancer. Int J Med Sci. 2018;15:659\u201365. https:\/\/doi.org\/10.7150\/ijms.24453","journal-title":"Int J Med Sci"},{"key":"2312_CR8","doi-asserted-by":"publisher","unstructured":"Kasprzak A, Adamek A. The Neuropeptide System and Colorectal Cancer Liver metastases: mechanisms and management. Int J Mol Sci. 2020;21. https:\/\/doi.org\/10.3390\/ijms21103494","DOI":"10.3390\/ijms21103494"},{"key":"2312_CR9","doi-asserted-by":"publisher","first-page":"3595","DOI":"10.2147\/OTT.S102356","volume":"9","author":"XY Chen","year":"2016","unstructured":"Chen XY, Ru GQ, Ma YY, Xie J, Chen WY, Wang HJ, Wang SB, Li L, Jin KT, He XL. Mou,high expression of substance P and its receptor neurokinin-1 receptor in colorectal cancer is associated with tumor progression and prognosis. Onco Targets Ther. 2016;9:3595\u2013602. https:\/\/doi.org\/10.2147\/OTT.S102356","journal-title":"Onco Targets Ther"},{"key":"2312_CR10","doi-asserted-by":"publisher","first-page":"3469","DOI":"10.1007\/s11033-020-05432-4","volume":"47","author":"S Lorestani","year":"2020","unstructured":"Lorestani S, Ghahremanloo A, Jangjoo A, Abedi M. Hashemy,evaluation of serum level of substance P and tissue distribution of NK-1 receptor in colorectal cancer. Mol Biol Rep. 2020;47:3469\u201374. https:\/\/doi.org\/10.1007\/s11033-020-05432-4","journal-title":"Mol Biol Rep"},{"key":"2312_CR11","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s00726-014-1736-9","volume":"46","author":"M Munoz","year":"2014","unstructured":"Munoz M. Covenas,involvement of substance P and the NK-1 receptor in human pathology. Amino Acids. 2014;46:1727\u201350. https:\/\/doi.org\/10.1007\/s00726-014-1736-9","journal-title":"Amino Acids"},{"key":"2312_CR12","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1111\/cge.13750","volume":"98","author":"S Ebrahimi","year":"2020","unstructured":"Ebrahimi S, Javid H, Alaei A. Hashemy,New insight into the role of substance P\/neurokinin-1 receptor system in breast cancer progression and its crosstalk with microRNAs. Clin Genet. 2020;98:322\u201330. https:\/\/doi.org\/10.1111\/cge.13750","journal-title":"Clin Genet"},{"key":"2312_CR13","doi-asserted-by":"publisher","first-page":"499","DOI":"10.22038\/ijbms.2021.52902.11945","volume":"24","author":"F Ghahremani","year":"2021","unstructured":"Ghahremani F, Sabbaghzadeh R, Ebrahimi S, Javid H, Ghahremani J. Hashemy,pathogenic role of the SP\/ NK1R system in GBM cells through inhibiting the thioredoxin system. Iran J Basic Med Sci. 2021;24:499\u2013505. https:\/\/doi.org\/10.22038\/ijbms.2021.52902.11945","journal-title":"Iran J Basic Med Sci"},{"key":"2312_CR14","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1007\/s11033-021-06928-3","volume":"49","author":"M Mozafari","year":"2022","unstructured":"Mozafari M, Ebrahimi S, Darban RA. Hashemy,potential in vitro therapeutic effects of targeting SP\/NK1R system in cervical cancer. Mol Biol Rep. 2022;49:1067\u201376. https:\/\/doi.org\/10.1007\/s11033-021-06928-3","journal-title":"Mol Biol Rep"},{"key":"2312_CR15","doi-asserted-by":"crossref","unstructured":"Ebrahimi S, Erfani B, Alalikhan A, Ghorbani H, Farzadnia M, Afshari AR, Mashkani B. and S.I. Hashemy,the in Vitro pro-inflammatory functions of the SP\/NK1R system in prostate Cancer: a focus on Nuclear factor-Kappa B (NF-\u03baB) and its pro-inflammatory target genes. Appl Biochem Biotechnol, 1\u201312 (2023).","DOI":"10.1007\/s12010-023-04495-w"},{"key":"2312_CR16","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1080\/13543776.2020.1769599","volume":"30","author":"M Mu\u00f1oz","year":"2020","unstructured":"Mu\u00f1oz M. Cove\u00f1as,Neurokinin receptor antagonism: a patent review (2014-present). Expert Opin Ther Pat. 2020;30:527\u201339.","journal-title":"Expert Opin Ther Pat"},{"key":"2312_CR17","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s10637-009-9218-8","volume":"28","author":"M Mu\u00f1oz","year":"2010","unstructured":"Mu\u00f1oz M, Rosso M. The NK-1 receptor antagonist aprepitant as a broad spectrum antitumor drug. Investig New Drugs. 2010;28:187\u201393.","journal-title":"Investig New Drugs"},{"key":"2312_CR18","doi-asserted-by":"publisher","unstructured":"Alsaeed MA, Ebrahimi S, Alalikhan A, Hashemi SF. and S.I. Hashemy,The Potential In Vitro Inhibitory Effects of Neurokinin-1 Receptor (NK-1R) Antagonist, Aprepitant, in Osteosarcoma Cell Migration and Metastasis. Biomed Res Int 2022, 8082608 (2022). https:\/\/doi.org\/10.1155\/2022\/8082608","DOI":"10.1155\/2022\/8082608"},{"key":"2312_CR19","doi-asserted-by":"publisher","first-page":"2682","DOI":"10.3390\/cancers12092682","volume":"12","author":"M Mu\u00f1oz","year":"2020","unstructured":"Mu\u00f1oz M. Cove\u00f1as,the neurokinin-1 receptor antagonist aprepitant: an intelligent bullet against cancer? Cancers. 2020;12:2682.","journal-title":"Cancers"},{"key":"2312_CR20","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/j.ejca.2015.03.024","volume":"51","author":"J Nishimura","year":"2015","unstructured":"Nishimura J, Satoh T, Fukunaga M, Takemoto H, Nakata K, Ide Y, Fukuzaki T, Kudo T, Miyake Y, Yasui M, Morita S, Sakai D, Uemura M, Hata T, Takemasa I, Mizushima T, Ohno Y, Yamamoto H, Sekimoto M, Nezu R, Doki Y, Mori M. T.G. Multi-center Clinical Study Group of Osaka,Combination antiemetic therapy with aprepitant\/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy (SENRI trial): a multicentre, randomised, controlled phase 3 trial. Eur J Cancer. 2015;51:1274\u201382. https:\/\/doi.org\/10.1016\/j.ejca.2015.03.024","journal-title":"Eur J Cancer"},{"key":"2312_CR21","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1093\/annonc\/mds541","volume":"24","author":"H Saito","year":"2013","unstructured":"Saito H, Yoshizawa H, Yoshimori K, Katakami N, Katsumata N, Kawahara M. Eguchi,Efficacy and safety of single-dose fosaprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving high-dose cisplatin: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial. Ann Oncol. 2013;24:1067\u201373. https:\/\/doi.org\/10.1093\/annonc\/mds541","journal-title":"Ann Oncol"},{"key":"2312_CR22","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.2147\/DDDT.S244648","volume":"14","author":"H Wu","year":"2020","unstructured":"Wu H, Cheng X, Huang F, Shao G, Meng Y, Wang L, Wang T, Jia X, Yang T, Wang X. Fu,Aprepitant sensitizes Acute myeloid leukemia cells to the cytotoxic effects of Cytosine Arabinoside in vitro and in vivo. Drug Des Devel Ther. 2020;14:2413\u201322. https:\/\/doi.org\/10.2147\/DDDT.S244648","journal-title":"Drug Des Devel Ther"},{"key":"2312_CR23","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1002\/biof.1953","volume":"49","author":"S Ebrahimi","year":"2023","unstructured":"Ebrahimi S, Mirzavi F, Hashemy SI, Khaleghi Ghadiri M, Stummer W. Gorji,the in vitro anti-cancer synergy of neurokinin-1 receptor antagonist, aprepitant, and 5-aminolevulinic acid in glioblastoma. BioFactors. 2023;49:900\u201311. https:\/\/doi.org\/10.1002\/biof.1953","journal-title":"BioFactors"},{"key":"2312_CR24","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.3892\/ol.2019.10474","volume":"18","author":"J Gu","year":"2019","unstructured":"Gu J, Li Z, Zhou J, Sun Z. Bai,Response prediction to oxaliplatin plus 5-fluorouracil chemotherapy in patients with colorectal cancer using a four-protein immunohistochemical model. Oncol Lett. 2019;18:2091\u2013101. https:\/\/doi.org\/10.3892\/ol.2019.10474","journal-title":"Oncol Lett"},{"key":"2312_CR25","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.3390\/molecules13081551","volume":"13","author":"N Zhang","year":"2008","unstructured":"Zhang N, Yin Y, Xu SJ. Chen,5-Fluorouracil: mechanisms of resistance and reversal strategies. Molecules. 2008;13:1551\u201369. https:\/\/doi.org\/10.3390\/molecules13081551","journal-title":"Molecules"},{"key":"2312_CR26","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1200\/JCO.1986.4.4.565","volume":"4","author":"F Richards","year":"1986","unstructured":"Richards F 2nd, Case LD, White DR, Muss HB, Spurr CL, Jackson DV, Cooper MR, Zekan P, Cruz J, Stuart JJ. Combination chemotherapy (5-fluorouracil, methyl-CCNU, mitomycin C) versus 5-fluorouracil alone for advanced previously untreated colorectal carcinoma. A phase III study of the Piedmont Oncology Association. J Clin Oncol. 1986;4:565\u201370. https:\/\/doi.org\/10.1200\/JCO.1986.4.4.565","journal-title":"J Clin Oncol"},{"key":"2312_CR27","first-page":"2473","volume":"4","author":"A Aquino","year":"1998","unstructured":"Aquino A, Prete SP, Greiner JW, Giuliani A, Graziani G, Turriziani M, De Filippi R, Masci G, Bonmassar E. De Vecchis,Effect of the combined treatment with 5-fluorouracil, gamma-interferon or folinic acid on carcinoembryonic antigen expression in colon cancer cells. Clin Cancer Res. 1998;4:2473\u201381.","journal-title":"Clin Cancer Res"},{"key":"2312_CR28","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1200\/JCO.2000.18.1.136","volume":"18","author":"S Giacchetti","year":"2000","unstructured":"Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C, Chollet P, Llory JF, Letourneau Y, Coudert B, Bertheaut-Cvitkovic F, Larregain-Fournier D, Le Rol A, Walter S, Adam R, Misset JL. Levi,Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2000;18:136\u201347. https:\/\/doi.org\/10.1200\/JCO.2000.18.1.136","journal-title":"J Clin Oncol"},{"key":"2312_CR29","doi-asserted-by":"publisher","first-page":"ii7","DOI":"10.1093\/annonc\/mdg723","volume":"14","author":"J-Y Douillard","year":"2003","unstructured":"Douillard J-Y, Sobrero A, Carnaghi C, Comella P, Diaz-Rubio E, Santoro A. Van Cutsem,metastatic colorectal cancer: integrating irinotecan into combination and sequential chemotherapy. Ann Oncol. 2003;14:ii7\u2013ii12.","journal-title":"Ann Oncol"},{"key":"2312_CR30","first-page":"3345","volume":"30","author":"B Pagan","year":"2010","unstructured":"Pagan B, Isidro AA, Coppola D, Chen Z, Ren Y, Wu J. Appleyard,Effect of a neurokinin-1 receptor antagonist in a rat model of colitis-associated colon cancer. Anticancer Res. 2010;30:3345\u201353.","journal-title":"Anticancer Res"},{"key":"2312_CR31","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.peptides.2015.04.026","volume":"72","author":"I Ramos-\u00c1lvarez","year":"2015","unstructured":"Ramos-\u00c1lvarez I, Moreno P, Mantey SA, Nakamura T, Nuche-Berenguer B, Moody TW, Coy DH. Jensen,insights into bombesin receptors and ligands: highlighting recent advances. Peptides. 2015;72:128\u201344.","journal-title":"Peptides"},{"key":"2312_CR32","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/j.pharep.2017.02.002","volume":"69","author":"M Munoz","year":"2017","unstructured":"Munoz M, Rosso M, Covenas R. The NK-1 receptor antagonist L-732,138 induces apoptosis in human gastrointestinal cancer cell lines. Pharmacol Rep. 2017;69:696\u2013701. https:\/\/doi.org\/10.1016\/j.pharep.2017.02.002","journal-title":"Pharmacol Rep"},{"key":"2312_CR33","doi-asserted-by":"publisher","unstructured":"Ghahremanloo A, Javid H, Afshari AR. and S.I. Hashemy,Investigation of the Role of Neurokinin-1 Receptor Inhibition Using Aprepitant in the Apoptotic Cell Death through PI3K\/Akt\/NF-kappaB Signal Transduction Pathways in Colon Cancer Cells. Biomed Res Int 2021, 1383878 (2021). https:\/\/doi.org\/10.1155\/2021\/1383878","DOI":"10.1155\/2021\/1383878"},{"key":"2312_CR34","doi-asserted-by":"publisher","first-page":"151","DOI":"10.3892\/ijo.2015.3016","volume":"47","author":"A Garnier","year":"2015","unstructured":"Garnier A, Vykoukal J, Hubertus J, Alt E, von Schweinitz D, Kappler R, Berger M. Ilmer,targeting the neurokinin-1 receptor inhibits growth of human colon cancer cells. Int J Oncol. 2015;47:151\u201360. https:\/\/doi.org\/10.3892\/ijo.2015.3016","journal-title":"Int J Oncol"},{"key":"2312_CR35","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s11060-015-1996-6","volume":"126","author":"RE Kast","year":"2016","unstructured":"Kast RE, Ramiro S, Llado S, Toro S, Covenas R. Munoz,Antitumor action of temozolomide, ritonavir and aprepitant against human glioma cells. J Neurooncol. 2016;126:425\u201331. https:\/\/doi.org\/10.1007\/s11060-015-1996-6","journal-title":"J Neurooncol"},{"key":"2312_CR36","doi-asserted-by":"publisher","unstructured":"R.E. Kast,Glioblastoma: synergy of growth promotion between CCL5 and NK-1R can be thwarted by blocking CCL5 with miraviroc, an FDA approved anti-HIV drug and blocking NK-1R with aprepitant, an FDA approved anti-nausea drug. J Clin Pharm Ther 35, 657\u201363 (2010). https:\/\/doi.org\/10.1111\/j.1365-2710.2009.01148.x","DOI":"10.1111\/j.1365-2710.2009.01148.x"},{"key":"2312_CR37","doi-asserted-by":"publisher","first-page":"119221","DOI":"10.1016\/j.bbamcr.2022.119221","volume":"1869","author":"S Ebrahimi","year":"2022","unstructured":"Ebrahimi S, Mirzavi F, Aghaee-Bakhtiari SH, Hashemy SI. SP\/NK1R system regulates carcinogenesis in prostate cancer: shedding light on the antitumoral function of aprepitant. Biochim et Biophys Acta (BBA)-Molecular Cell Res. 2022;1869:119221.","journal-title":"Biochim et Biophys Acta (BBA)-Molecular Cell Res"},{"key":"2312_CR38","doi-asserted-by":"publisher","first-page":"4893","DOI":"10.1007\/s11033-022-07348-7","volume":"49","author":"M Golestaneh","year":"2022","unstructured":"Golestaneh M, Firoozrai M, Javid H. Hashemy,the substance P\/ neurokinin-1 receptor signaling pathway mediates metastasis in human colorectal SW480 cancer cells. Mol Biol Rep. 2022;49:4893\u2013900. https:\/\/doi.org\/10.1007\/s11033-022-07348-7","journal-title":"Mol Biol Rep"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-024-02312-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-024-02312-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-024-02312-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T00:00:57Z","timestamp":1709078457000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-024-02312-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,10]]},"references-count":38,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["2312"],"URL":"https:\/\/doi.org\/10.1007\/s12032-024-02312-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3666066\/v1","asserted-by":"object"}]},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,10]]},"assertion":[{"value":"26 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"70"}}